SLC7A5 expression is indicative of a poor prognosis in pancreas cancer [22, 24], melanoma [25], bile duct adenocarcinomas [26], and clear cell renal cell carcinoma [27]. Here, SLC7A5 is linked to clear cell renal carcinoma.